Biomarkers and Nicotine Pouches: Why Measuring Exposure Matters for Evidence-Based RegulationJuly 14, 2026
The Hidden Smoking Burden Among People Who Use Drugs: Why Tobacco Harm Reduction Cannot Be IgnoredJuly 1, 2026
Beyond Endgame Thinking: What The Guardian Editorial and Palau’s UN Proposal Reveal About the Future of Nicotine GovernanceJune 25, 2026
The EU’s Nicotine Crossroads: Will Europe Follow the Evidence or Treat All Products Like Cigarettes?June 24, 2026
Europe’s Regulatory Pivot: Why More Governments Are Targeting Smoke-Free Nicotine ProductsJune 17, 2026
Nicotine Pouches as Medicine: What Canada, Australia, France, and Brazil Reveal About the Pharmaceutical Classification ModelJune 11, 2026
France’s Nicotine Pouch Ban and Sweden’s Response: A Growing Debate Over Risk-Proportionate RegulationJune 3, 2026
UK Advertising Restrictions for Nicotine Products: What Stakeholders Should Watch Before June 2027June 2, 2026
A Milestone in Evidence-Based Nicotine Regulation: FDA’s Environmental Assessment for Nicotine PouchesMay 25, 2026
Brazil’s 4mg Pharmaceutical Model: What ANVISA’s Direction Could Mean for Innovation, Consumers, and Latin America’s Regulatory FutureMay 19, 2026
Portugal’s Challenge to the UK Tobacco Ban: A New Test for Post-Brexit Regulatory SovereigntyMay 11, 2026
Nicotine Analogs and the Next Regulatory Frontier: Emerging Questions for Science, Policy, and Product GovernanceMay 8, 2026
Argentina Rewrites Its Nicotine Policy Framework: From Prohibition to Regulatory IntegrationMay 7, 2026
France’s Nicotine Pouch Ban and Europe’s Regulatory Divide: What It Reveals About EU Policy FragmentationMay 6, 2026
Navigating EU Taxation for Alternative Nicotine Products: Key Insights from EVO NXT 2026April 22, 2026
🚭 GINN Initial Analysis: Commission’s TPD Evaluation Overstates Success, Undermines Harm ReductionApril 6, 2026
GINN Insight: Ireland’s EU Presidency: Public Health, Prevention, and Policy CoordinationApril 2, 2026
GINN Insight: Article 5.3 and Harm Reduction: Governance Safeguard or Policy Constraint?March 3, 2026
GINN Insight: The Cypriot Presidency Proposal and the Future of EU Excise Policy for Nicotine PouchesFebruary 26, 2026
FDA’s Review of ZYN’s Modified Risk Applications Signals a Turning Point for Nicotine PolicyFebruary 16, 2026
The EU’s Tobacco Policy Expert Group Is Ending — What Comes Next Matters More Than EverFebruary 11, 2026
Fragmented Nicotine Laws, Youth Protection, and the Case for Coherent Regulation in EuropeJanuary 21, 2026
Fiscal Dependence, Regulatory Friction, and the Challenge of Transitioning Away from CigarettesDecember 29, 2025
Global Institute For Novel Nicotine Submission Call For Evidence – Tobacco and Vapes Bill November 2025December 10, 2025
COP11 Shows a Divided World: Why Europe Must Not Import WHO’s Anti-Harm-Reduction StanceNovember 27, 2025
An Evolution in Public Health: The FDA’s Ongoing Recognition of Tobacco Harm ReductionNovember 6, 2025
Policy Momentum on Nicotine Pouches in the UK: Balancing Regulation, Harm Reduction, and Youth ProtectionNovember 4, 2025
GINN’s Position on the EU Excise Directive Revision: Toward a Clear, Fair, and Evidence-Based FrameworkNovember 3, 2025
Portugal Introduces Nicotine Pouch Tax: A Step Toward Regulation and Responsible Harm ReductionOctober 23, 2025
Kenya at a Crossroads: Regulating Nicotine Pouches and the Future of Tobacco Harm ReductionAugust 8, 2025
Portugal Pushes Back: The Economic and Public Health Stakes in the EU Tobacco Tax ReformAugust 6, 2025
Smoke-Free Products Behind the Counter: Lessons from Pharmacist-Only Access in Canada and AustraliaAugust 5, 2025
Sweden Stands Firm: Why the EU’s Tobacco Tax Proposal Risks Undermining a Proven Public Health ModelJuly 15, 2025
The Rise of Tobacco-Free Nicotine Pouches in the UK: A New Era After the Disposable Vape BanJuly 15, 2025
Taxing Trouble: Why Europe’s Tobacco Strategy Must Balance Health Goals with Economic RealitiesJuly 7, 2025
